Case Report: Recurrent cerebral embolism secondary to direct cardiac invasion by lung adenocarcinoma - Takeaways - MDSpire

Case Report: Recurrent cerebral embolism secondary to direct cardiac invasion by lung adenocarcinoma

  • By

  • Xiangxiong Wu

  • Shenwen He

  • Yayao Huo

  • Yuying Wu

  • Xiaoying Li

  • Ying Yang

  • Dawei Dong

  • June 24, 2026

  • 0 min

Share

  • 1

    A 41-year-old woman experienced recurrent cerebral embolism due to direct cardiac infiltration by lung adenocarcinoma.

  • 2

    The patient underwent two successful mechanical thrombectomies for occlusions in the left and right middle cerebral arteries.

  • 3

    Imaging revealed a right lung adenocarcinoma infiltrating the pericardium, pulmonary vein, and left atrium.

  • 4

    Following treatment with chemotherapy and anticoagulation, the patient remained free of further embolic events during follow-up.

  • 5

    This case highlights the importance of considering tumor-related strokes in younger patients without traditional risk factors.

Original Source(s)

Case Report: Recurrent cerebral embolism secondary to direct cardiac invasion by lung adenocarcinoma

  • by Xiangxiong Wu, Shenwen He, Yayao Huo, Yuying Wu, Xiaoying Li, Ying Yang, Dawei Dong

  • June 24, 2026

Related Content

Training on PD-L1 scoring in non-small cell lung cancer with high intra- and inter-reader agreement: results of a worldwide microscopic/digital image-based training of 751 pathologists

What the Biggest ASCO Cancer Research Updates Could Mean for Patients

Each year, the American Society of Clinical Oncology Annual Meeting brings together cancer specialists from around the world to share the research most likely to shape the next chapter of cancer care. This year’s major updates point to several important themes: more precise treatment, smarter use of surgery and chemotherapy, new approaches for difficult-to-treat cancers and a growing recognition that supportive care, including exercise, can be part of cancer treatment planning.

  • by

  • June 8, 2026

  • 10 min
This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min